Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- Men who have been diagnosed with prostate cancer (specifically adenocarcinoma) that has spread to other parts of the body, confirmed through a tissue or cell sample
- People whose general health and ability to carry out daily activities meets a certain minimum level (confirm with trial site)
- People who have had their cancer staged using a CT scan and bone scan, or a specialised type of scan called a PET PSMA or choline scan
- People for whom PSA (a prostate-related protein measured in the blood) results are available from the start of hormone treatment and from around six months after starting that treatment
- People who are currently receiving or have completed treatment with at least one of the following hormone-blocking medications: abiraterone acetate, apalutamide, darolutamide, or enzalutamide
- People for whom detailed background information — including health history, test results, and other medical data — is available from the start of treatment
- People who have signed a consent form agreeing to take part in the study
Who may not be able to join:
- People who do not have a confirmed tissue-based diagnosis of prostate cancer
- People who did not have any follow-up medical appointments after starting treatment
- People for whom the required background medical information from the start of treatment is not available
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Roberto Iacovelli, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phone: +390630157373
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the survival based on the PSA response at six months from the beginning of ARPI in patients with mCSPC.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.